In summary - safe to give LintuzumabAc225 at low doses with intensive chemo. Counts come back. Given study population, LintuzumabAc225 appears to add in eliminating disease; would not have expected as high or as long of a response with salvage in this population.

Safety results: I was mostly interested excessive cytopenias from adding a cytopenia producing agent to intensive salvage chemotherapy. Higher dose LintuzumabAc225 monotherapy did not have other toxicities of note other than transient transaminitis. 7/

Patients Enrolled: To me, this was the most interesting part. This study occurred in the post-Venetoclax era. Reviewing patients chronologically, 2019 on, patients with bad disease got Ven/HMA even if fit, relapses got Ven/HMA, even while label is for ND-AML. 5/

With trials few and far between that yield disease clearance, we brainstormed how this active drug may be better delivered. We hypothesized if chemo first could clear some disease, then lower doses of Lintuzumab-Ac225 may be adequate to clear residual disease, more safely. 3/